3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Hepatocellular
2
Ovarian Neoplasms
1
Neoplasms
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiotoxicity
1
Breast Neoplasms
1
Interventions
Control Groups
2
Atorvastatin
2
sacubitril and valsartan sodium hydrate drug combination
1
pertuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
dapagliflozin
1
candesartan
1
Trastuzumab
1
Sodium Chloride
1
Simendan
1
Pyruvic Acid
1
Population Groups
1
Ogivri
1
Metoprolol
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Eplerenone
1
Carvedilol
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Heart Failure
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled